COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

References

• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Feb 14;21(3):335–337. published online.
   Web of Science ®Google Scholar
• Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. [published online ahead of print, 2020 Mar 25]. JAMA Oncol. 2020;e200980. DOI:10.1001/jamaoncol.2020.0980
   Web of Science ®Google Scholar
• Xia Y, Jin R, Zhao J, et al. Risk of COVID-19 for cancer patients. Lancet Oncol. 2020 Mar 3; ii: S1470-2045(20)30150–9. DOI:10.1016/S1470-2045(20)30150-9.
   PubMedGoogle Scholar
• Wang J, Luo Q, Chen R, et al. Susceptibility analysis of COVID-19 in smokers based on ACE2. Preprints. 2020;2020030078. DOI:10.20944/preprints202003.0078.v1.
   Google Scholar
• Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017 Apr 14;21(1):89.
   PubMed Web of Science ®Google Scholar
• Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features. Cancers (Basel). 2019 Mar;11(3):305.
   Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.
   PubMed Web of Science ®Google Scholar
• Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Mar 12;ii: ciaa247. DOI:10.1093/cid/ciaa247.
   Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 16:ii: S0140-6736(20)30628–0. DOI:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu YL, Li ZP, et al. Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19). J Infect. 2020 Mar 3;ii: S0163-4453(20)30104–3. DOI:10.1016/j.jinf.2020.02.022.
   Google Scholar
• Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Feb 24;ii: S1473-3099(20)30086–4. DOI:10.1016/S1473-3099(20)30086-4.
   Web of Science ®Google Scholar
• Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020Mar;10:200823.
   Google Scholar
• Tian S, Hu W, Niu L, et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020 Feb 27; ii: S1556-0864(20)30132–5. DOI:10.1016/j.jtho.2020.02.010.
   Web of Science ®Google Scholar
• Barton LM, Duval EJ, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153(6):725–733.
   PubMed Web of Science ®Google Scholar
• Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19 [published online ahead of print, 2020 May 6]. Ann Intern Med. 2020;M20–2003. DOI:10.7326/M20-2003.
   PubMedGoogle Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience [published online ahead of print, 2020 Apr 6]. J Med Virol. 2020. DOI:10.1002/jmv.25801
   Web of Science ®Google Scholar
• Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55(3):105923.
   PubMed Web of Science ®Google Scholar
• Nicastri E, Petrosillo N, Ascoli BT, et al. National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management. Infect Dis Rep. 2020 Mar 16;12(1):8543. DOI:10.4081/idr.2020.8543
   Web of Science ®Google Scholar
• Sohrabi C, Alsafi Z, O’Neill, M. et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020 Feb 26;76: 71–76.
   PubMed Web of Science ®Google Scholar
• Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020 Mar 11;323(15):1499.
   PubMed Web of Science ®Google Scholar
• Huang Y, Fan H, Li N, et al. Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: systematic review and network meta-analysis. Cancer Med. 2019 May;8(5):2664–2674.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264–iv266.
   PubMed Web of Science ®Google Scholar
• Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017;9:207–213.
   PubMed Web of Science ®Google Scholar
• Cadranel J, Canellas A, Matton L, et al. Pulmonary complications of immune checkpoint inhibitors in patients with non-small cell lung cancer. Eur Respir Rev. 2019 Oct 9;28(153):ii: 190058.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017 Mar;35(7):709–717. Epub 2016 Sep 30.
   PubMed Web of Science ®Google Scholar
• Widmann G, Nguyen VA, Plaickner J, et al. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep. 2016;5(11):59.
   PubMedGoogle Scholar
• Larsen BT, Chae JM, Dixit AS, et al. Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis. Am J Surg Pathol. 2019 Oct;43(10):1331–1340..
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–734.
   PubMed Web of Science ®Google Scholar
• Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020;94:119–124.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune response in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020. DOI:10.12932/AP-200220-0772
   PubMed Web of Science ®Google Scholar
• Kritas SK, Ronconi G, Caraffa A, et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1). [published online ahead of print, 2020 Feb 4]. DOI:10.23812/20-Editorial-Kritas.
   Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1. [published online ahead of print, 2020 Mar 14].
   PubMed Web of Science ®Google Scholar
• Conti P, Gallenga CE, Tetè G, et al. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 [published online ahead of print, 2020 Mar 31]. J Biol Regul Homeost Agents. 2020;34(2). DOI:10.23812/Editorial-Conti-2
   Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa248.
   Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374. DOI:10.1038/s41577-020-0311-8
   Google Scholar
• Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Liu YH, Zang XY, Wang JC, et al. Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy. Biomed Pharmacother. 2019 Dec;120:109437. Epub 2019 Oct 4.
   PubMed Web of Science ®Google Scholar
• Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res. 2019 Mar 1;25(5):1557–1563.
   PubMed Web of Science ®Google Scholar
• Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64(12):Dec.
   Web of Science ®Google Scholar
• Fessas P, Possamai LA, Clark J, et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020 Feb;159(2):167–177. Epub 2019 Nov 19.
   PubMed Web of Science ®Google Scholar
• Ye G, Li Y, Lu M, et al. Experience of different upper respiratory tract sampling strategies for detection of COVID-19. J Hosp Infect. 2020 Mar 12;ii: S0195-6701(20)30111–0. DOI:10.1016/j.jhin.2020.03.012.
   PubMed Web of Science ®Google Scholar
• Pang J, Wang MX, Ang IYH, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020 Feb 26;9(3):ii: E623.
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473.
   PubMed Web of Science ®Google Scholar
• Tang C, Wang Y, Lv H, et al. Caution against corticosteroid-based COVID-19 treatment [published online ahead of print, 2020 May 25]. Lancet. 2020;S0140-6736(20)30749–2. DOI:10.1016/S0140-6736(20)30749-2
   PubMed Web of Science ®Google Scholar
• Bonomi L, Ghilardi L, Arnoldi E, et al. A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab [published online ahead of print, 2020 Mar 31]. J Thorac Oncol. 2020;S1556-0864(20)30285–9. DOI:10.1016/j.jtho.2020.03.021
   PubMed Web of Science ®Google Scholar